Synapse - Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial

Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial Meeting Abstract

Authors:	Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; Epstein-Peterson, Z. D.; Palomba, M. L.; Stuver, R.; Noy, A.; Martinova, A.; Wood, L.; Grieve, C.; Amador, W. R.; Vardhana, S. A.; Zelenetz, A. D.; Leslie, L. A.; Roswarski, J. L.; Dunleavy, K.; Goy, A.; Salles, G.
Abstract Title:	Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
Meeting Title:	66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	144
Issue:	Suppl. 1
Meeting Dates:	2024 Dec 7-10
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-11-05
Start Page:	340
End Page:	341
Language:	English
ACCESSION:	WOS:001412768200040
DOI:	10.1182/blood-2024-205046
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos